The total number of records retrieved from this search are 12. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_845	Virus nameHerpes simplex virus	Virus strainHSV-G207	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant in ICP34.5 and ICPC6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineEpithelial ovarian carcinoma	Cell lineA2780	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityMinimal cytotoxic to mesothelial cells	AssayBeta galacosidase colorimetric proliferation assay	In-vitro virus concentration0.01 MOI	In-vitro result35% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID10770637
IDOV_5160	Virus nameVesicular stomatitis virus	Virus strainVSV-deltaGP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus lacking envelope protein G	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of vienna	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738655
IDOV_5161	Virus nameVesicular stomatitis virus	Virus strainVSV-MqdeltaG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationAttenuated strain with 4 mutation in M protein and lacking G protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of vienna	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738655
IDOV_5162	Virus nameVesicular stomatitis virus	Virus strainVSV-deltaGP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus lacking envelope protein G	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of vienna	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738655
IDOV_5163	Virus nameVesicular stomatitis virus	Virus strainVSV-MqdeltaG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationAttenuated strain with 4 mutation in M protein and lacking G protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of vienna	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27738655
IDOV_5284	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.1 PFU	In-vitro result85% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5285	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.33 PFU	In-vitro result70% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5286	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration1 PFU	In-vitro result42% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5287	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration3.3 PFU	In-vitro result10% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5288	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration10 PFU	In-vitro result5% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5289	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration33 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5290	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineA2780	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration100 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340